Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Arbutus Biopharma

Evaluate

Thumbnail
February 08, 2023

Arrowhead's hep B plans in jeopardy

Thumbnail
August 26, 2022

With Covid pandemic over, Moderna heads to the courts

Article image
Vantage logo
June 30, 2022

Key data catalysts for the industry’s small players

Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.

Article image
Vantage logo
September 02, 2021

Assembly disassembles again

Article image
Vantage logo
May 04, 2021

Roivant rewrites the Spac script, again

After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.

Article image
Vantage logo
January 27, 2021

Vir becomes a biotech bubble poster child

The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.

Article image
Vantage logo
November 06, 2020

Hep B cure failure hits the Assembly line

Article image
Vantage logo
August 28, 2020

EASL 2020 – Assembly finds a partner as hepatitis B inches forward

As fresh data confirm the promise of RNAi technology in hepatitis B, Assembly brings on Arbutus for its combo strategy.

Article image
Vantage logo
July 27, 2020

Curevac muddies the Moderna/Arbutus waters further

The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.

Article image
Vantage logo
July 24, 2020

The Covid-19 vaccine battle just got interesting

A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.

Article image
Vantage logo
May 19, 2020

Arbutus finally gets out of the hep B starting blocks

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up